Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cofetuzumab pelidotin
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cofetuzumab pelidotin is an experimental antibody-drug conjugate (ADC) designed for the treatment of cancer. It consists of a humanized anti-protein tyrosine kinase 7 (PTK7) monoclonal antibody (hu6M024, IgG1) linked via a cleavable valine-citrulline linker to auristatin-0101 (Aur0101), a potent microtubule inhibitor. The ADC selectively binds to PTK7-expressing tumor cells; upon internalization and cleavage within the cell, it releases the cytotoxic auristatin payload that disrupts microtubules and induces mitotic arrest and apoptosis. PTK7 is overexpressed in several cancers including non-small cell lung cancer (NSCLC), ovarian cancer, breast cancer—especially triple-negative breast cancer—and others. Early clinical trials have shown promising antitumor activity in these indications[1][3][5][6][7].
- Other names
- cofetuzumab pelidotinPF-06647020PF06647020PF 06647020ABBV-647ABBV647ABBV 647
02
Targets
PTK7 (Protein tyrosine kinase 7)
Beyond the preview
Go deeper on cofetuzumab pelidotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cofetuzumab pelidotin.